25 March 2020
PROFESSOR JOANNE HACKETT IS APPOINTED AS BOARD CHAIR OF BIOS
Cambridge, UK – 25 March, 2020 – BIOS, a full-stack neural interface platform startup, has announced that Professor Joanne Hackett has been appointed as chair of the board. Professor Hackett brings over 20 years of experience and leadership roles in the biotech and life sciences sector. An accomplished entrepreneur, scientist, and strategist, she has deep expertise in scaling and commercialising biotech innovations.
"BIOS is an agile, fast paced and ambitious entrepreneurial biotech. These are crucial characteristics of successful early stage companies. The interface between technology and the human body is one of the most important fields helping us move beyond incremental changes to our approach to health. The platform that BIOS is developing could lead to a much bigger step change and is something I could not wait to be a part of," said Professor Hackett. "I have been fortunate enough to develop a global portfolio of companies I am involved with, each of which presents a unique challenge and a tremendous opportunity to learn. I look forward to helping BIOS realise its potential, and I am excited by the opportunity to learn more about such an exciting field."
Emil Hewage, CEO and co-founder of BIOS, said: “Professor Hackett’s background as a clinical researcher and senior executive at both Fortune 500 companies and startups have given her a unique ability to identify innovations and bring them to maturity. As one of the key global figures in personalised medicine, she immediately enhances the presence of BIOS in the sector. She is an experienced and highly skilled operator, and we’re thrilled to have her support and guidance as we continue our rapid growth.”
BIOS, founded 2015, and backed by UK and North American investors, is now entering its clinical development phase and is laying the groundwork for commercialisation of its technology. At this pivotal stage of growth, Professor Hackett’s experience and skills will be an invaluable addition.
About BIOS Health
BIOS is developing a full-stack neural interface platform that uses AI to decode and encode the signals from the brain to the body, to treat chronic health conditions. There are three parts to our technology. Firstly, our implanted neural interface connects directly with the nerves to isolate the signals that travel between the brain and the body. Secondly, our AI decodes and encodes this neural information from hundreds of thousands of individual neurons, tens of thousands of times per second, and sends corrected signals back into the body. Lastly, using this neural code, we can build a whole digital healthcare treatment. For a person with a severe chronic health condition, that means their condition could be managed via the nervous system directly by AI, giving personalised and accurate treatments, where the burden of pills and doctor visits become a second resort rather than a daily reality.
Co-founded by Cambridge University graduates Emil Hewage, a computational neuroscientist, and Oliver Armitage, a biomechanical engineer, BIOS is made up of a wide range of experts from neuroscience and artificial intelligence, software engineering and medicine. Combined our team brings 300+ peer-reviewed publications, 6,000+ clinical procedures, and 10+ first-of-kind medical devices.
Head of Communications & Partnerships